This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Augmentation of Dopaminergic Agents for Major Depressive Disorder

Chi-Un Pae, Ashwin A. Patkar, and Prakash S. Masand

Published: May 15, 2009

Article Abstract

Letter to the Editor

Sir: We read with great interest the randomized,
double-blind, placebo-controlled clinical trial (RCT) entitled
"Osmotic-Release Oral System Methylphenidate Augmentation
of Antidepressant Monotherapy in Major Depressive Disorder:
Results of a Double-Blind, Randomized, Placebo-Controlled
Trial" (osmotic-release oral system methylphenidate [OROS
MPH] N = 73, placebo N = 72; mean dose of OROS MPH =
36.4 mg/day), which followed our earlier 4-week RCT (OROS
MPH N = 30, placebo N = 30; mean dose of OROS MPH =
34.2 mg/day). In their article, Ravindran et al. referenced our
study only in the form of an abstract that was presented in a scientific
meeting, without providing any detailed comparisons between
the 2 studies. We therefore will briefly introduce our
study results using a meta-analytic approach to extract findings
from the 2 studies in order to achieve better sample power. We
also provide meta-analytic findings from 4 RCTs of modafinil
augmentation for unipolar and bipolar depression.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 70

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...